scispace - formally typeset
D

David Ginsburg

Researcher at University of Michigan

Publications -  277
Citations -  20935

David Ginsburg is an academic researcher from University of Michigan. The author has contributed to research in topics: Von Willebrand factor & Gene. The author has an hindex of 76, co-authored 266 publications receiving 19779 citations. Previous affiliations of David Ginsburg include Parke-Davis & Life Sciences Institute.

Papers
More filters
Journal ArticleDOI

Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene.

TL;DR: Data demonstrate a direct correlation between the genetically determined level of PAI-1 expression and the extent of collagen accumulation that follows inflammatory lung injury and strongly support the hypothesis that alterations in fibrinolytic activity influenceThe extent of pulmonary fibrosis that occurs after inflammatory injury.
Journal ArticleDOI

Detectable clonal mosaicism from birth to old age and its relationship to cancer.

Cathy C. Laurie, +72 more
- 01 Jun 2012 - 
TL;DR: Clonal mosaicism for large chromosomal anomalies (duplications, deletions and uniparental disomy) is detected using SNP microarray data from over 50,000 subjects recruited for genome-wide association studies to identify common deleted regions with genes previously associated with hematological cancers.
Journal ArticleDOI

Genome-wide mapping of DNase hypersensitive sites using massively parallel signature sequencing (MPSS)

TL;DR: High-throughput analysis, using massively parallel signature sequencing (MPSS), of 230,000 tags from a DNase library generated from quiescent human CD4+ T cells identifies 14,190 clusters of sequences that group within close proximity to each other that represent valid DNase HS sites.
Journal ArticleDOI

Impact, Diagnosis and Treatment of von Willebrand Disease*

TL;DR: There are at least 580,000 persons with symptomatic VWD worldwide who could benefit from appropriate diagnosis followed by replacement or pharmacological therapy, and 80% of these persons live in the developing world.